Global & Public Health (all articles)
Study: mRNA vaccine is associated with decreased SARS-CoV-2 viral load in individuals with breakthrough infection, suggesting a role in suppressing onward transmission
30 Mar, 2021 | 03:25h | UTC
Commentaries on Twitter
https://twitter.com/nresearchnews/status/1376667763914240000
(Thread – Click for more)
New @NatureMedicine: The concern about asymptomatic transmission addressed in nearly 5,000 people after 1st dose of mRNA vaccine (~2 -5 wks). Viral load markedly reduced (high Ct). Supports vaccine effect for blocking or strongly reducing chance of spreadhttps://t.co/mmJmZPZfHK pic.twitter.com/0TTf4cFZed
— Eric Topol (@EricTopol) March 29, 2021
Cochrane Library Editorial: Contested effects and chaotic policies: the 2020 story of (hydroxy) chloroquine for treating COVID‐19
28 Mar, 2021 | 22:55h | UTCCommentary and Infographic: Is chloroquine or hydroxychloroquine useful in treating people with COVID-19, or in preventing infection in people who have been exposed to the virus? – Cochrane Library
Original review: Chloroquine or hydroxychloroquine for prevention and treatment of COVID‐19 – Cochrane Library
Commentary on Twitter
New #VisualAbstract for the @Cochrane_IDG systematic review on #Chloroquine or #hydroxychloroquine for prevention and treatment of #COVID19 https://t.co/U7TnMzQTil Many thanks to @tylerdau & @cg_coleman from @EmoryMedicine pic.twitter.com/tlFKKa31E8
— The Cochrane Library (@CochraneLibrary) March 25, 2021
Another study indicates SARS-CoV-2 variant B.1.351, but not variant B.1.1.7, has partial resistance to neutralizing antibodies generated by natural infection or mRNA vaccination
28 Mar, 2021 | 22:53h | UTC
Commentaries on Twitter
Now a peer-reviewed pub in a top journal, this elegant study clearly shows that variant B.1.351 isn't stopped by antibodies from prior infection or the Pfizer vax. We'll have revised vaccines, but we don't yet. Please behave accordingly. https://t.co/w8GHPDB7aL
— EQV Analytics 🇺🇦😷🔬🪷 (@AnalyticsEqv) March 27, 2021
New @NatureMedicine, further data on immune response after vaccination to 2 variants, B.1.1.7 (UK) and B.1.351 (SA). Reinforcing recent reports, the latter is more of an immune evader, and may pose vulnerability for reinfection post-vaccinehttps://t.co/w8xFc3fkh5 pic.twitter.com/i7DAnjSZwE
— Eric Topol (@EricTopol) March 26, 2021
Editorial | Remote by default general practice: must we, should we, dare we?
28 Mar, 2021 | 22:18h | UTC
https://twitter.com/trishgreenhalgh/status/1375408196303650818
Quadrivalent influenza nanoparticle vaccines induce broad protection against a wide variety of seasonal and pandemic influenza strains in animal models
28 Mar, 2021 | 22:01h | UTCQuadrivalent influenza nanoparticle vaccines induce broad protection – Nature
Commentary: Nanoparticle flu vaccine blocks seasonal and pandemic strains – University of Washington School of Medicine
Covid-19: Middle aged women face greater risk of debilitating long term symptoms
28 Mar, 2021 | 22:49h | UTCCovid-19: Middle aged women face greater risk of debilitating long term symptoms – The BMJ
Linked Opinion: The stigma is real for people living with long covid – The BMJ Opinion
Routine asymptomatic testing strategies for airline travel during the COVID-19 pandemic: a simulation study
28 Mar, 2021 | 22:34h | UTC
Commentary on Twitter (thread – click for more)
1/N Our new study published in @TheLancetInfDis on #COVID19 testing strategies for safer airline travel. Getting tested before and after air travel can prevent the spread of #COVID19 and make flying safer. Collab led by the singular Dr. @mathewkiang. https://t.co/mO3JrMIhOp pic.twitter.com/0yBhux4eKb
— Nathan Lo (@NathanLo3579) March 22, 2021
Persistent neurologic symptoms and cognitive dysfunction in non‐hospitalized Covid‐19 “long haulers”
28 Mar, 2021 | 22:48h | UTCCommentary: 85% of COVID-19 long-haulers have multiple brain-related symptoms – LiveScience AND ‘Brain fog’ and other neurologic symptoms can last for months after Covid – NBC News AND Neurologic Symptoms Persistent for Many COVID-19 ‘Long-Haulers’ – Health Day
International travel‐related control measures to contain the COVID‐19 pandemic: a rapid review
28 Mar, 2021 | 22:38h | UTC
Commentary on Twitter
Can international travel‐related control measures contain the spread of the #COVIV19 #pandemic? https://t.co/9AC4OVJL83 Updated @CochranePH rapid review looks at evidence around closing borders, restricting travel, screening/testing, & quarantining newly‐arrived. pic.twitter.com/LKeXoEGPGp
— The Cochrane Library (@CochraneLibrary) March 26, 2021
Pushing back against U.S. health officials, AstraZeneca says new analysis confirms efficacy of its Covid-19 vaccine
26 Mar, 2021 | 09:01h | UTCNews release: AZD1222 US Phase III primary analysis confirms safety and efficacy – AstraZeneca
See also: Latest results put Oxford–AstraZeneca COVID vaccine back on track – Nature AND AstraZeneca’s absurd and unprecedented dispute with regulators, explained – Vox AND Expert reaction to press release from AstraZeneca announcing primary data on safety and efficacy from the US trial of the Oxford-AstraZeneca COVID-19 vaccine – Science Media Centre AND AstraZeneca says COVID-19 vaccine 76% effective in new analysis, to seek U.S. approval – Reuters AND AstraZeneca’s new data showing Covid vaccine slightly less effective than suggested doesn’t worry experts – The Guardian AND Latest AstraZeneca Report Supports Effectiveness Of COVID Vaccine – NPR
Practice Pointer: Remote management of Covid-19 using home pulse oximetry and virtual ward support
26 Mar, 2021 | 09:05h | UTCRemote management of covid-19 using home pulse oximetry and virtual ward support – The BMJ
Related: Virtual clinics are reassuring but sometimes daunting – The BMJ
Commentary on Twitter
https://twitter.com/trishgreenhalgh/status/1375110854094520322
Experts: 3-foot rule in schools problematic in light of COVID variants
26 Mar, 2021 | 08:56h | UTCExperts: 3-foot rule in schools problematic in light of COVID variants – CIDRAP
Related: CDC Guidance for schools says students can now stay 3 feet apart, rather than 6
Variant-proof vaccines — invest now for the next pandemic
26 Mar, 2021 | 08:48h | UTCVariant-proof vaccines — invest now for the next pandemic – Nature
Another study shows increased transmissibility of SARS-CoV-2 lineage B.1.1.7 with a 50% to 100% higher reproduction number
26 Mar, 2021 | 08:57h | UTCAssessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England – Nature
Related: Study confirms higher transmissibility of SARS-CoV-2 lineage B.1.1.7 (study and commentary)
Commentary on Twitter
Just published @nature: Transmissibility of the B.1.1.7 (UK) variant https://t.co/dsMge8bB83 "A substantial transmission advantage with a 50 to 100% higher reproduction number"
Secondary attack rates were 30-40% higher than ancestral strain (non-VOC); no age gradient by modeling pic.twitter.com/870A3PojyF— Eric Topol (@EricTopol) March 25, 2021
The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study
26 Mar, 2021 | 08:44h | UTCThe first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study – The Lancet
Commentary: Africa needs local solutions to face the COVID-19 pandemic – The Lancet
Commentary on Twitter (thread – click for more)
NEW—Continent-wide analysis suggests 30% increase in daily #COVID19 infections during rise of Africa's second wave compared with peak of the first. Authors urge improved data reporting, testing capacity, and renewed adherence to public health measures. https://t.co/bQq2F1Zrg0 pic.twitter.com/5TTSW7mkzF
— The Lancet (@TheLancet) March 25, 2021
Covid: The London bus trip that saved maybe a million lives (about the creation of the RECOVERY Trial)
26 Mar, 2021 | 08:53h | UTCCovid: The London bus trip that saved maybe a million lives – BBC
Related: Covid-19: The Inside Story of the RECOVERY Trial
Commentary on Twitter
Very cool story by @JamesTGallagher about a convo on a London bus that led to the creation of the RECOVERY trial, which has been a shining (& too rare) example of how to do critical research in a pandemic. Bravo @PeterHorby & @MartinLandray h/t @hildabast https://t.co/BRSJLSFXdc
— Helen Branswell 🇨🇦 (@HelenBranswell) March 25, 2021
M-A: Incidence and prevalence of tuberculosis in incarcerated populations
25 Mar, 2021 | 08:09h | UTCCommentary: Tuberculosis in prisons: an unintended sentence? – The Lancet Public Health
Commentary on Twitter (thread – click for more)
https://twitter.com/LeoMarti_EpiTB/status/1374073141195014145
USPSTF Statement: Current evidence is insufficient to recommend screening for hearing loss in older adults
24 Mar, 2021 | 08:12h | UTCScreening for Hearing Loss in Older Adults – U.S. Preventive Services Task Force
Editorial: Screening for Hearing Loss in Older Adults: Insufficient Evidence Does Not Mean Insufficient Benefit – JAMA AND United States Preventive Services Task Force Recommendation for Hearing-Loss Screening Among Older Adults: An Opportunity in Insufficient Evidence – AMA Otolaryngology-Head & Neck Surgery AND USPSTF Recommendations for Hearing Loss Screening in Asymptomatic Older Adults—A Case of Missing Evidence and Missing Treatment Options – JAMA Network Open
Evidence Report: Screening for Hearing Loss in Older Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force – JAMA
Author interview: USPSTF Recommendation: Screening for Hearing Loss in Older Adults – JAMA
JAMA Patient Page: Screening for Hearing Loss in Older Adults
WHO Campaign | World Tuberculosis Day 2021: The Clock Is Ticking
24 Mar, 2021 | 08:16h | UTCWorld Tuberculosis Day 2021: The Clock Is Ticking – World Health Organization
Perspective | Leveraging Open Science to Accelerate Research
25 Mar, 2021 | 08:37h | UTCLeveraging Open Science to Accelerate Research – New England Journal of Medicine
Audio Interview: What earlier epidemics teach us about Covid-19
25 Mar, 2021 | 08:33h | UTCAudio Interview: What Earlier Epidemics Teach Us about Covid-19 – New England Journal of Medicine
Perspective | New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications
25 Mar, 2021 | 08:34h | UTC
Systematic review: Rapid, point‐of‐care antigen and molecular‐based tests for diagnosis of SARS‐CoV‐2 infection
25 Mar, 2021 | 08:38h | UTCCommentaries: Updated Cochrane review assesses how accurate rapid tests are for detecting COVID-19 – Wiley AND Expert reaction to updated Cochrane review of studies on accuracy of rapid tests (including lateral flow and molecular tests) to detect SARS-CoV-2 – Science Media Centre
NICE publishes single guideline for managing COVID-19
24 Mar, 2021 | 08:42h | UTCNews release: COVID-19 rapid guideline: managing COVID-19 – National Institute for Health and Care Excellence
Commentary on Twitter
Today NICE has published a single guideline for managing COVID-19, which brings together content from previous rapid COVID-19 guidance and evidence summaries. Read more: https://t.co/3O5yzpHK9e pic.twitter.com/DyD7lcLX8v
— NICE (@NICEComms) March 23, 2021
Preventing the next pandemic: the power of a global viral surveillance network
25 Mar, 2021 | 08:29h | UTCPreventing the next pandemic: the power of a global viral surveillance network – The BMJ